Page 49 - Query Get News Today

Researchers found increased incidence of Clostridioides difficile infection among patients with esophageal atresia with or without tracheoesophageal fistula undergoing proton pump inhibitor therapy, according to a poster. “Esophageal atresia/tracheoesophageal fistula (EA/TEF) patients are at an increased risk for GERD and its associated complications. Current ESPGHAN-NASPGHAN consensus

The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences. The system works by providing localized heat therapy to soften or liquefy thickened meibum inside the glands to allow for more effective gland clearance.

Moderna on Monday said that a booster dose of its messenger RNA COVID-19 vaccine, given at the authorized dose of 50 µg, offered a 37-fold increase in protection against the omicron variant, compared with pre-boost levels. Protection levels rose 83-fold compared with pre-boost levels following a booster dose of 100 µg.

The FDA on Monday approved ViiV Healthcare’s cabotegravir as the first long-acting injectable for HIV PrEP. The medication, which will be known as Apretude, is administered every 2 months after two initial injections that are given 1 month apart. The FDA approved it for at-risk adults and adolescents weighing at least 77 pounds.

Rapid implementation of a cystic fibrosis care model including telemedicine was successful for monitoring lung function and identifying exacerbations during the COVID-19 pandemic, according to data published in Chest.The care model also enabled monitoring of BMI and decreased use of antibiotics.

Intrauterine contraceptive devices appeared to have systemic effects on the body akin to those associated with hormone replacement therapy, a small study showed. Although women have previously reported experiencing adverse events after receiving an intrauterine contraceptive device (IUD) that were similar to adverse events associated with oral hormonal replacement, “manufacturers claim that

The CDC’s Advisory Committee on Immunization Practices recently issued a universal recommendation that all adults aged 19 to 59 years receive the hepatitis B vaccine. “This new recommendation by the ACIP will be instrumental in raising adult hepatitis B vaccination rates in the U.S. to levels that will allow us to finally eliminate hepatitis B in this country,” Rita Kuwahara,

There have been rare reports of myocarditis and pericarditis among people who have received a COVID-19 messenger RNA vaccine, with cases occurring especially among male adolescents and young adults, according to the CDC.

Eli Lilly and Co. announced positive top-line phase 3 results of mirikizumab for moderate to severe ulcerative colitis. According to a press release, mirikizumab at 1 year in the LUCENT-2 trial met its primary endpoint of clinical remission. In addition, it met its secondary endpoints.

Self-reported drug use by teens decreased during the pandemic, according to an NIH-funded study.